IBDEI3AW ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,238,0)
 ;;=INJECTION MEDICATIONS^2^37
 ;;^UTILITY(U,$J,358.4,239,0)
 ;;=ULTRASOUND^3^37
 ;;^UTILITY(U,$J,358.4,240,0)
 ;;=NEW PATIENT^2^38
 ;;^UTILITY(U,$J,358.4,241,0)
 ;;=ESTABLISHED PATIENT^1^38
 ;;^UTILITY(U,$J,358.4,242,0)
 ;;=CONSULTATIONS^3^38
 ;;^UTILITY(U,$J,358.4,243,0)
 ;;=COMMON DIAGNOSES^1^39
 ;;^UTILITY(U,$J,358.4,244,0)
 ;;=CRYSTAL ARTHROPATHIES^2^39
 ;;^UTILITY(U,$J,358.4,245,0)
 ;;=JOINT DISORDERS^6^39
 ;;^UTILITY(U,$J,358.4,246,0)
 ;;=MISCELLANEOUS^7^39
 ;;^UTILITY(U,$J,358.4,247,0)
 ;;=NERVOUS SYSTEM^8^39
 ;;^UTILITY(U,$J,358.4,248,0)
 ;;=OSTEOARTHRITIS^9^39
 ;;^UTILITY(U,$J,358.4,249,0)
 ;;=OSTEOMYELITIS^10^39
 ;;^UTILITY(U,$J,358.4,250,0)
 ;;=OSTEOPOROSIS^11^39
 ;;^UTILITY(U,$J,358.4,251,0)
 ;;=PYOGENIC ARTHRITIS^13^39
 ;;^UTILITY(U,$J,358.4,252,0)
 ;;=SPINE DISORDERS^14^39
 ;;^UTILITY(U,$J,358.4,253,0)
 ;;=TENDINITIS & BURSITIS^16^39
 ;;^UTILITY(U,$J,358.4,254,0)
 ;;=VASCULAR DISORDERS^17^39
 ;;^UTILITY(U,$J,358.4,255,0)
 ;;=VASCULITIS CONDITIONS^18^39
 ;;^UTILITY(U,$J,358.4,256,0)
 ;;=INFECTIONS^3^39
 ;;^UTILITY(U,$J,358.4,257,0)
 ;;=INT DERANGEMENT OF KNEE^4^39
 ;;^UTILITY(U,$J,358.4,258,0)
 ;;=OTHER INFLAMMATORY^12^39
 ;;^UTILITY(U,$J,358.4,259,0)
 ;;=HISTORY OF^5^39
 ;;^UTILITY(U,$J,358.4,260,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^15^39
 ;;^UTILITY(U,$J,358.4,261,0)
 ;;=SUBSTANCE USE & MISC SERVICES^6^40
 ;;^UTILITY(U,$J,358.4,262,0)
 ;;=DIAGNOSTIC EVALUATION^1^40
 ;;^UTILITY(U,$J,358.4,263,0)
 ;;=PSYCHOTHERAPY ^4^40
 ;;^UTILITY(U,$J,358.4,264,0)
 ;;=OTHER CODES^3^40
 ;;^UTILITY(U,$J,358.4,265,0)
 ;;=TOBACCO USE CESSATION^7^40
 ;;^UTILITY(U,$J,358.4,266,0)
 ;;=MEDICATIONS^2^40
 ;;^UTILITY(U,$J,358.4,267,0)
 ;;=SELF-MANAGEMENT^5^40
 ;;^UTILITY(U,$J,358.4,268,0)
 ;;=ESTABLISHED PATIENT^1^41
 ;;^UTILITY(U,$J,358.4,269,0)
 ;;=OUTPATIENT CONSULTATIONS^3^41
 ;;^UTILITY(U,$J,358.4,270,0)
 ;;=NEW PATIENT^2^41
 ;;^UTILITY(U,$J,358.4,271,0)
 ;;=INPATIENT CONSULTATIONS^4^41
 ;;^UTILITY(U,$J,358.4,272,0)
 ;;=INITIAL HOSPITAL CARE^5^41
 ;;^UTILITY(U,$J,358.4,273,0)
 ;;=HOSPITAL CARE DISCHARGE ^7^41
 ;;^UTILITY(U,$J,358.4,274,0)
 ;;=INITIAL OBSERVATION CARE^8^41
 ;;^UTILITY(U,$J,358.4,275,0)
 ;;=OBSERVATION CARE DISCHARGE SERVICES^10^41
 ;;^UTILITY(U,$J,358.4,276,0)
 ;;=INPT or OBS ADMIT & D/C SAME DAY^11^41
 ;;^UTILITY(U,$J,358.4,277,0)
 ;;=SUBSEQUENT HOSPITAL CARE^6^41
 ;;^UTILITY(U,$J,358.4,278,0)
 ;;=OBSERVATION SUBSEQUENT CARE^9^41
 ;;^UTILITY(U,$J,358.4,279,0)
 ;;=DOMICILLIARY EST PATIENT^12^41
 ;;^UTILITY(U,$J,358.4,280,0)
 ;;=DOMICILLIARY NEW PATIENT^13^41
 ;;^UTILITY(U,$J,358.4,281,0)
 ;;=HOME VISITS EST PATIENT^14^41
 ;;^UTILITY(U,$J,358.4,282,0)
 ;;=HOME VISITS NEW PATIENT^15^41
 ;;^UTILITY(U,$J,358.4,283,0)
 ;;=TEAM CONFERENCE^16^41
 ;;^UTILITY(U,$J,358.4,284,0)
 ;;=ABUSE,NEGLECT, & VIOLENCE^1^42
 ;;^UTILITY(U,$J,358.4,285,0)
 ;;=ANXIETY DISORDERS^2^42
 ;;^UTILITY(U,$J,358.4,286,0)
 ;;=BIPOLAR & RELATED DISORDERS^3^42
 ;;^UTILITY(U,$J,358.4,287,0)
 ;;=NEUROCOGNITIVE DISORDERS^17^42
 ;;^UTILITY(U,$J,358.4,288,0)
 ;;=DEPRESSIVE DISORDERS^7^42
 ;;^UTILITY(U,$J,358.4,289,0)
 ;;=DISSOCIATIVE DISORDERS ^9^42
 ;;^UTILITY(U,$J,358.4,290,0)
 ;;=FEEDING & EATING DISORDERS^12^42
 ;;^UTILITY(U,$J,358.4,291,0)
 ;;=EDUC/OCCUPATIONAL PROBLEMS^10^42
 ;;^UTILITY(U,$J,358.4,292,0)
 ;;=GENDER DYSPHORIA^14^42
 ;;^UTILITY(U,$J,358.4,293,0)
 ;;=HOUSING/ECONOMIC PROBLEMS^15^42
 ;;^UTILITY(U,$J,358.4,294,0)
 ;;=MEDICATION ADVERSE EFFECTS^16^42
